Abstract:Hypoxia is a common feature of solid tumours affecting their biology and response to therapy. One of the main transcription factors activated by hypoxia is hypoxia-inducible factor (HIF), which regulates the expression of genes involved in various aspects of tumourigenesis including proliferative capacity, angiogenesis, immune evasion, metabolic reprogramming, extracellular matrix (ECM) remodelling, and cell migration. This can negatively impact patient outcomes by inducing therapeutic resistance. The importance of hypoxia is clearly demonstrated by continued research into finding clinically relevant hypoxia biomarkers, and hypoxia-targeting therapies. One of the problems is the lack of clinically applicable methods of hypoxia detection, and lack of standardisation. Additionally, a lot of the methods of detecting hypoxia do not take into consideration the complexity of the hypoxic tumour microenvironment (TME). Therefore, this needs further elucidation as approximately 50% of solid tumours are hypoxic. The ECM is important component of the hypoxic TME, and is developed by both cancer associated fibroblasts (CAFs) and tumour cells. However, it is important to distinguish the different roles to develop both biomarkers and novel compounds. Fibronectin (FN), collagen (COL) and hyaluronic acid (HA) are important components of the ECM that create ECM fibres. These fibres are crosslinked by specific enzymes including lysyl oxidase (LOX) which regulates the stiffness of tumours and induces fibrosis. This is partially regulated by HIFs. The review highlights the importance of understanding the role of matrix stiffness in different solid tumours as current data shows contradictory results on the impact on therapeutic resistance. The review also indicates that further research is needed into identifying different CAF subtypes and their exact roles; with some showing pro-tumorigenic capacity and others having anti-tumorigenic roles. This has made it difficult to fully elucidate the role of CAFs within the TME. However, it is clear that this is an important area of research that requires unravelling as current strategies to target CAFs have resulted in worsened prognosis. The role of immune cells within the tumour microenvironment is also discussed as hypoxia has been associated with modulating immune cells to create an anti-tumorigenic environment. Which has led to the development of immunotherapies including PD-L1. These hypoxia-induced changes can confer resistance to conventional therapies, such as chemotherapy, radiotherapy, and immunotherapy. This review summarizes the current knowledge on the impact of hypoxia on the TME and its implications for therapy resistance. It also discusses the potential of hypoxia biomarkers as prognostic and predictive indictors of treatment response, as well as the challenges and opportunities of targeting hypoxia in clinical trials.

The Extracellular Matrix and Hypoxia

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Crosstalk between Hypoxia and Extracellular Matrix in the Tumor Microenvironment in Breast Cancer

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

Extracellular matrix and its therapeutic potential for cancer treatment

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

The Extracellular Matrix and Vesicles Modulate the Breast Tumor Microenvironment

Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers

The Role of Extracellular Matrix Proteins in Breast Cancer

Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics

Extracellular Matrix in Mammary Gland Development and Breast Cancer Progression

The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis

Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment

Tumorigenesis and Progression As A Consequence of Hypoxic TME：A Prospective View upon Breast Cancer Therapeutic Targets

The Mechanism Between Epithelial Mesenchymal Transition in Breast Cancer and Hypoxia Microenvironment

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer

Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy

EMT: A New Vision of Hypoxia Promoting Cancer Progression

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions